Paula Jaeger Tenorio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paula Jaeger Tenorio has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alan Chaves dos Santos
Ctr Atencao Mulher, Inst Med Integral Prof Fernando Figueira, Recife, PE, Brazil
1 shared publication - Alex Sandro Rolland Souza
Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Brazil; Universidade Católica de Pernambuco (UNICAP), Brazil; Universidade Federal de Pernambuco (UFPE), Brazil
1 shared publication - Elias Almeida Silva Barbosa
University Federal of Pernambuco (UFPE)- Center of bioscience (CB)- Brazil
1 shared publication - Gabriela Oliveira Lobo Pereira da Costa
Universidade Maurício de Nassau, Brazil
1 shared publication - Gabriella de Almeida Figueredo Praciano
Universidade Católica de Pernambuco, Brasil
1 shared publication - Gustavo Fonseca de Albuquerque Souza
Instituto de Medicina Integral Professor Fernando Figueira, Brazil
1 shared publication
Latest Publications
- Open Access
- 31 May 2023
- Published by Taylor & Francis in Journal of Psychosomatic Obstetrics & Gynecology
- Vol. 44 (1) , 2210747
Symptoms of anxiety and depression in women with gestational trophoblastic disease compared to women who had a miscarriage: a cross-sectional study
This study was conducted between March 2020 and February 2021 to analyze anxiety and depression symptoms in 64 women with gestational trophoblastic disease (GTD) and 99 women who had miscarried. The Hospital Anxiety and Depression Scale (HADS) was applied by telephone three months after pregnancy loss. Multivariate analysis was performed using hierarchical logistic regression to evaluate associations between variables. Probable anxiety (HADS-A ≥ 8) and depression (HADS-D ≥ 8) were found in 53.1% and 43.8% of the GTD group and 49.5% and 39.4% of the miscarriage group, with no difference between the groups. Severe symptoms of anxiety (HADS-A 15-21) and depression (HADS-D 15-21) were found, respectively, in 12.5% and 4.7% of the GTD group and in 9.1% and 4.0% of the miscarriage group, also with no difference between the groups. Lack of partner support proved a risk factor for anxiety and depression, while poor education increased the risk of depression symptoms 3.43-fold following pregnancy loss. In conclusion, three months after pregnancy loss the frequency of anxiety and depression symptoms was similarly high in both groups, with poor education and lack of partner support being significant risk factors for the subsequent development of psychiatric morbidity.
- 31 May 2023
- Published by Taylor & Francis in Journal of Psychosomatic Obstetrics & Gynecology
- Vol. 44 (1) , 2210747
Open AccessSymptoms of anxiety and depression in women with gestational trophoblastic disease compared to women who had a miscarriage: a cross-sectional study
This study was conducted between March 2020 and February 2021 to analyze anxiety and depression symptoms in 64 women with gestational trophoblastic disease (GTD) and 99 women who had miscarried. The Hospital Anxiety and Depression Scale (HADS) was applied by telephone three months after pregnancy loss. Multivariate analysis was performed using hierarchical logistic regression to evaluate associations between variables. Probable anxiety (HADS-A ≥ 8) and depression (HADS-D ≥ 8) were found in 53.1% and 43.8% of the GTD group and 49.5% and 39.4% of the miscarriage group, with no difference between the groups. Severe symptoms of anxiety (HADS-A 15-21) and depression (HADS-D 15-21) were found, respectively, in 12.5% and 4.7% of the GTD group and in 9.1% and 4.0% of the miscarriage group, also with no difference between the groups. Lack of partner support proved a risk factor for anxiety and depression, while poor education increased the risk of depression symptoms 3.43-fold following pregnancy loss. In conclusion, three months after pregnancy loss the frequency of anxiety and depression symptoms was similarly high in both groups, with poor education and lack of partner support being significant risk factors for the subsequent development of psychiatric morbidity.
- Open Access
- 1 February 2021
- Published by FapUNIFESP (SciELO) in Revista Brasileira de Saúde Materno Infantil
- Vol. 21 (suppl 1) , 133-143
The testing for COVID-19 in symptomatic patients as a protective factor against stress, anxiety, and depression
Objectives: to determine the frequency of stress, anxiety, and depression symptoms in symptomatic patients for COVID-19. To evaluate the associated factors involved in these variants. Methods: between May/June of 2020, it was conducted a prospective cross-section study with symptomatic participants for COVID-19 (n=300). It was applied an online questionnaire and the DASS-21 to evaluate the mental health of participants. Results: it was observed that 28.6%, 29.7% and 27% of the participants showed severe/extreme levels symptoms of stress, anxiety, and depression, respectively. The testing for COVID-19 application had constituted a protective factor for the development of psychiatric morbidity, once it had shown significant association in the low frequencies of severe/extreme depression [Odds Ratio (OR)]= 0.26; p=0.002) and stress (OR=0.39; p=0.01). Conclusion: individuals that are symptomatic for COVID-19 are a vulnerable group that may present high symptomatology for depression, anxiety, and stress. The identification of psychiatric morbidity frequency and its associated factors may contribute for the development of mental health strategies aiming at the prevention and mitigation of psychological impact in COVID-19 symptomatic population during the pandemic.
- 1 February 2021
- Published by FapUNIFESP (SciELO) in Revista Brasileira de Saúde Materno Infantil
- Vol. 21 (suppl 1) , 133-143
Open AccessThe testing for COVID-19 in symptomatic patients as a protective factor against stress, anxiety, and depression
Objectives: to determine the frequency of stress, anxiety, and depression symptoms in symptomatic patients for COVID-19. To evaluate the associated factors involved in these variants. Methods: between May/June of 2020, it was conducted a prospective cross-section study with symptomatic participants for COVID-19 (n=300). It was applied an online questionnaire and the DASS-21 to evaluate the mental health of participants. Results: it was observed that 28.6%, 29.7% and 27% of the participants showed severe/extreme levels symptoms of stress, anxiety, and depression, respectively. The testing for COVID-19 application had constituted a protective factor for the development of psychiatric morbidity, once it had shown significant association in the low frequencies of severe/extreme depression [Odds Ratio (OR)]= 0.26; p=0.002) and stress (OR=0.39; p=0.01). Conclusion: individuals that are symptomatic for COVID-19 are a vulnerable group that may present high symptomatology for depression, anxiety, and stress. The identification of psychiatric morbidity frequency and its associated factors may contribute for the development of mental health strategies aiming at the prevention and mitigation of psychological impact in COVID-19 symptomatic population during the pandemic.